COMMUNIQUÉS West-GlobeNewswire

Portola Pharmaceuticals Enters into $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management
01/03/2019
Agreement Provides Financial Flexibility for the Ongoing Commercialization of Andexxa® and Launch Preparations in Europe SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® ( [...]
Sanofi : CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes
01/03/2019
CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes PARIS and THE WOODLANDS, TX - March 1, 2019 - The European Medicines Agency's Committee for Medicinal Products for Human Use ( [...]
Sanofi : Le CHMP recommande ZynquistaTM (sotagliflozine) pour le traitement du diabète de type 1 chez l'adulte
01/03/2019
Le CHMP recommande ZynquistaTM (sotagliflozine) pour le traitement du diabète de type 1 chez l'adulte Paris et The Woodlands (Texas) - Le 1 er mars 2019 - Le Comité des médicaments à usage humain (CHMP, Committee for [...]
Celldex to Report Full Year 2018 Business/Financial Results and Host Corporate Update Call
01/03/2019
HAMPTON, N.J., March 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2018 financial results on Thursday, March 7, 2019 after the U.S. financial markets [...]
Krystal Biotech to Present at the Cowen and Company 39th Annual Health Care Conference
01/03/2019
PITTSBURGH, March 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin [...]
Zealand Pharma to attend Credit Suisse and BioCapital Healthcare Conferences
01/03/2019
Press release – No. 04 / 2019 Zealand Pharma to attend Credit Suisse and BioCapital Healthcare Conferences Copenhagen, March 1, 2019 – Adam Steensberg, Interim Chief Executive Officer, will attend the Credit Suisse 2019 [...]
Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
01/03/2019
BOSTON, March 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today [...]
Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA
01/03/2019
CRANBURY, N.J., March 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today the submission of its Investigational New Drug (IND) application with the U.S. Food and Drug [...]
Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019
01/03/2019
-- Orally administered PRN2246 achieved full BTK occupancy in peripheral blood -- -- PRN2246 exhibited blood-brain barrier permeability and CNS exposure -- -- Sanofi to lead Phase 2 development for people with Multiple [...]
Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
01/03/2019
ROCKVILLE, Md., March 01, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers [...]
Wellness Matrix Group To Initiate State-of-the-Art DNA Program
01/03/2019
LOS ANGELES, March 01, 2019 (GLOBE NEWSWIRE) -- Wellness Matrix Group, Inc. ( WMGR ), a technologically advanced Company in the Virtual Reality Artificial Intelligence health care model space, released details today on [...]
Bionano Genomics Launches New Capabilities of the Saphyr System to Significantly Increase Its Cost Effectiveness, Speed and Ease of Use for Whole Human Genome Structural Variation Analysis and Digital Cytogenetics
01/03/2019
The Saphyr platform is being used to drive the emergence of digital cytogenetics – a streamlined, comprehensive and cost-effective approach to modernize the clinical detection of structural variations which are at the [...]
Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate (QBREXZA™ (glycopyrronium) cloth) in Patients with Primary Axillary Hyperhidrosis
01/03/2019
Three poster presentations from Phase 3 glycopyrronium tosylate clinical program address clinically relevant questions impacting people living with primary axillary hyperhidrosis New analysis from ATMOS-1 and ATMOS-2 [...]
Tower One Appoints New Chief Financial Officer
01/03/2019
VANCOUVER, British Columbia, March 01, 2019 (GLOBE NEWSWIRE) -- TOWER ONE WIRELESS CORP. (CSE: TO) (OTCQB: TOWTF) (Frankfurt: 1P3N) (“Tower One” or the “Company”) announces it has appointed Santiago F. Rossi to the [...]
CHMP Recommends Zynquista™ (Sotagliflozin) for the Treatment of Adults With Type 1 Diabetes
01/03/2019
PARIS and THE WOODLANDS, Texas, March 01, 2019 (GLOBE NEWSWIRE) -- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Marketing Authorization of [...]
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
01/03/2019
First and only therapy approved for FCS, a serious and rare disease with no approved treatment options BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an [...]
European CHMP Adopts Positive Opinion on Ondexxya™ (andexanet alfa) Portola Pharmaceuticals’ Factor Xa Inhibitor Reversal Agent
01/03/2019
SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]
Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
01/03/2019
SAN DIEGO, March 01, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2018, after the [...]
TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting
01/03/2019
Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 MS trial NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing [...]

Pages